Research and Markets (http://www.researchandmarkets.com/research/46xvs5/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Relapsing Remitting Multiple Sclerosis (RRMS) Overview
  3. Therapeutics Development
  4. Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview
  5. Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis
  6. Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies
  7. Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes
  8. Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies
  13. Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes
  14. Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development
  • AbbVie Inc.
  • Actelion Ltd
  • Allozyne, Inc.
  • Amarna Therapeutics B.V.
  • Antisense Therapeutics Limited
  • Biocon Limited
  • Biogen, Inc.
  • Cognosci, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Forward Pharma A/S
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Iltoo Pharma
  • Mapi Pharma Ltd.
  • MedImmune, LLC
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Neurotec Pharma SL
  • Novartis AG
  • Octapharma AG
  • Opexa Therapeutics, Inc.
  • RedHill Biopharma Ltd.
  • Sanofi
  • Synthetic Biologics, Inc.
  • Teva Pharmaceutical Industries Limited
  • Xenetic Biosciences plc
  • Zydus Cadila Healthcare Limited

For more information visit http://www.researchandmarkets.com/research/46xvs5/relapsing